To address these issues, Chen and co‐workers developed a hybrid CMN system comprising platelet‐derived NVs, M1‐macrophage‐derived NVs, and genetically engineered cancer‐cell‐derived NVs that overexpress high‐affinity SIRPα variants. The gene discussed is SIRPA; the disease is cancer.